Targeting a system in the body to slow down pancreatic cancer and related blood clots
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
This study is looking at how certain proteins in the body might help pancreatic cancer grow and also increase the risk of blood clots, and it aims to find ways to slow down the cancer while keeping patients safe from these complications.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10458582 on NIH RePORTER |
What this research studies
This research investigates the link between pancreatic cancer progression and blood clotting complications. It focuses on how certain proteins in the body, particularly Tissue Factor, contribute to both tumor growth and increased risk of blood clots in patients with pancreatic ductal adenocarcinoma (PDAC). By targeting the plasminogen activation system, the research aims to reduce tumor growth while also addressing the associated thromboembolic risks. Patients may be involved in studies that explore these mechanisms and potential treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who may be experiencing complications related to blood clotting.
Not a fit: Patients with other types of cancer or those without pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow pancreatic cancer progression and reduce the risk of blood clots in affected patients.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Flick, Matthew J. — Univ of North Carolina Chapel Hill
- Study coordinator: Flick, Matthew J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.